What happened to the Mesoblast Limited (ASX:MSB) share price?

After surging to a new 52-week in September, the Mesoblast Limited (ASX:MSB) share price has collapsed dramatically recently. Let’s look at the reason for its decline, and investigate whether the company is still a good investment.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

After surging to a 52-week high of $5.70 by late September, shares in ASX biotechnology company Mesoblast Limited (ASX: MSB) have come crashing back down to earth this month. The company has shed close to 45% of its market cap in the last few weeks, after receiving an underwhelming response from the US Federal Drugs Administration (FDA) concerning its flagship treatment, remestemcel-L, marketed under the brand name RYONCIL. As of Friday afternoon, Mesoblast shares were trading at just $3.11.

The funny thing is that this has all happened before. Back in August, the Mesoblast share price plunged almost 40% after nervous investors sparked a sell-off, fearing a negative outcome from a meeting between Mesoblast and the Oncologic Drugs Advisory Committee (ODAC), an independent panel that advises the FDA. In that instance, the committee voted overwhelmingly that the available data supported the efficacy of RYONCIL in paediatric patients. Once the market learned of the positive outcome, the Mesoblast share price rebounded just as swiftly.

This time around, things haven’t worked out so well for Mesoblast. So, what is actually happening here?

Despite the advice from ODAC, the FDA stated that it would like Mesoblast to conduct at least one more study to prove the effectiveness of RYONCIL. This comes as a pretty heavy blow to Mesoblast, as the company had already been making preparations to launch RYONCIL in the US. These plans will now all need to be put on hold while Mesoblast conducts the additional study – this means potentially significant delays and possibly significant investment.

No wonder the market reacted with shock and investors decided to dump their shares.

But it’s also bad news for patients. RYONCIL is designed to treat various inflammatory diseases including chronic heart failure and graft versus host disease (GvHD). GvHD is a potentially life-threatening complication that can occur in up to 50% of cancer patients who have received a bone marrow transplant. Currently, there is no approved treatment in the US for GvHD in children under 12.

Mesoblast is now applying for an accelerated approval with the FDA, which could mean RYONCIL would be approved, but under the condition that a further study is conducted. And meanwhile, it is conducting a phase 3 trial using RYONCIL as a treatment for sufferers of acute respiratory distress syndrome (ARDS) brought on by coronavirus.

In a press release, Mesoblast CEO Dr Silviu Itescu said that the company is “working tirelessly to bring remestemcel-L to patients with life-threatening inflammatory conditions, including SR-aGVHD [steroid-refractory acute graft versus host disease] and COVID-19 ARDS.”

Where to from here?

I have to admit to being quite bullish on Mesoblast, so it’s disappointing that they haven’t come away from their meeting with the FDA with a better outcome, particularly after ODAC voted so resoundingly in their favour. However, this does show the extreme volatility that can occur in the share prices of companies like Mesoblast, where a great deal of their commercial viability is dependent on a single event.

That being said, I think Mesoblast is still definitely worth keeping on your watch list as a possible future growth stock. Their technology is cutting edge and they still have significant cash on hand after a capital raise back in May. However, in the meantime, perhaps your money would be better invested in more mature and diversified healthcare companies like ResMed CDI (ASX: RMD) or CSL Limited (ASX: CSL).

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

Rhys Brock has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers